ERNA — Stock Film
STOCK FILMSCENE 1/11ERNA · $4.54
Stock Expert AI presents
ERNA
Ernexa Therapeutics Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Ernexa Therapeutics Inc. A quick introduction.

On the stock market since 1991, it operates in the world of health and science. It has 5 employees. Now — the numbers.

on the stock market since 1991
5 employees
$1.4M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $490K
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
25 buy7 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
19
very weak

Clearly below the class average.

FINANCIAL STRENGTH
10
very weak

Clearly below the class average.

VALUATION
68
strong

Clearly above the class average — a step short of the very top.

GROWTH
42
weak

Clearly below the class average.

PRICE MOMENTUM
16
very weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled2/10
Thin profit on each sale3/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
Executives are buying their own stock

Over the last 12 months, company executives reported 25 buys and 7 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $14.1M against $0 in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ERNA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ERNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film